Keros Therapeutics Inc (KROS) - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4923271013

Blood Disorder, Cancer, Pulmonary Hypertension, Obesity, Neuromuscular Diseases

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative treatments for patients with disorders related to dysfunctional signaling of the transforming growth factor-beta (TGF-β) family of proteins.

The company's lead product candidate, KER-050, is being developed to treat low blood cell counts, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. These are types of blood disorders that can lead to severe fatigue, weakness, and increased risk of infections.

In addition to KER-050, Keros Therapeutics is also developing KER-012, which is in Phase II clinical trial for the treatment of pulmonary arterial hypertension and cardiovascular disorders. Pulmonary arterial hypertension is a serious condition that affects the lungs and heart, leading to shortness of breath, fatigue, and limited physical activity.

The company is also working on KER-065, which is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. Obesity is a major public health concern, and neuromuscular diseases can cause muscle weakness, wasting, and paralysis.

Keros Therapeutics has a collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. This partnership aims to accelerate the development and commercialization of KER-050 for the treatment of patients with myelodysplastic syndromes and myelofibrosis.

Founded in 2015, Keros Therapeutics is headquartered in Lexington, Massachusetts, and is committed to improving the lives of patients with serious diseases. For more information, visit their website at

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Keros Therapeutics Inc (KROS) - Stock & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Keros Therapeutics Inc (KROS) - Stock & Dividends

KROS Stock Overview

Market Cap in USD 1,757m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2020-04-08

KROS Stock Ratings

Growth 5y 30.9
Fundamental -
Dividend -
Rel. Performance vs Sector 1.65
Analysts 4.80/5
Fair Price Momentum 39.81 USD
Fair Price DCF -

KROS Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

KROS Growth Ratios

Growth 12m 13.00%
Growth Correlation 12m 33%
Growth Correlation 3m -78%
CAGR 5y 20.89%
CAGR/Mean DD 5y 0.55
Sharpe Ratio 12m 0.14
Alpha vs SP500 12m -26.20
Beta vs SP500 5y weekly 1.60
ValueRay RSI 10.52
Volatility GJR Garch 1y 49.19%
Price / SMA 50 -17.48%
Price / SMA 200 -4.52%
Current Volume 742.1k
Average Volume 20d 311.4k

External Links for KROS Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of KROS stocks?
As of June 18, 2024, the stock is trading at USD 44.58 with a total of 742,097 shares traded.
Over the past week, the price has changed by -8.76%, over one month by -14.73%, over three months by -30.19% and over the past year by +17.97%.
What are the forecast for KROS stock price target?
According to ValueRays Forecast Model, KROS Keros Therapeutics Inc will be worth about 45.1 in June 2025. The stock is currently trading at 44.58. This means that the stock has a potential upside of +1.05%.
Issuer Forecast Upside
Wallstreet Target Price 90.6 103
Analysts Target Price 88.9 99.3
ValueRay Target Price 45.1 1.05